Gary Layton

2.7k citations
44 papers · 1.9k · 1 hit paper · h-index 22

Impact in

Papers in

Gary Layton

44 papers receiving 1.9k citations

Gary Layton's Hit Papers

P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study 2014 · 349 citations
3490+4+8Years since publication100200300

Peers

Gary Layton
Comparison fields: 5 of 102
  • Pulmonary and Respiratory Medicine 884
  • Cardiology and Cardiovascular Medicine 508
  • Physiology 80
  • Sensory Systems 81
  • Physiology 428
Replace Pierre‐Olivier Girodet with:
Pierre‐Olivier Girodet France
Michael Adamzik Germany
Peter Schnuelle Germany
H Favre Switzerland
Neil R. Aggarwal United States
Misha Luyer Netherlands
S. Nordgren Sweden
Full‐Young Chang Taiwan
N. Håkan Wallén Sweden
Markus Zorn Germany
Gary Layton relative to Pierre‐Olivier Girodet France Pierre‐Olivier Girodet's profile →
Citations per field
00.5×6.2×
Pierre‐Olivier Girodet · 1×
Citations per year

Countries citing papers authored by Gary Layton

Since Specialization
Citations

This map shows the geographic impact of Gary Layton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Layton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Layton more than expected).

Fields of papers citing papers by Gary Layton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Layton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Layton. The network helps show where Gary Layton may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary Layton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary Layton Line = papers co-authored together Gary Layton links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.

#Work
1
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
Hit paper breakdown →
2014349
2 2011266
3 2011186
4 2014141
5 2017128
6 2009105
7 201898
8 200383
9 200663
10 201054
11 201646
12 200934
13 201934
14 199733
15 199830
16 200726
17 200325
18 200424
19 201423
20 201923

About Gary Layton

Gary Layton is a scholar working on Infectious Diseases, Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine, Physiology and Molecular Biology, having authored 44 papers that have together received 1.9k indexed citations. Recurring topics across this work include Pulmonary Hypertension Research and Treatments (7 papers), HIV/AIDS drug development and treatment (7 papers), Antifungal resistance and susceptibility (6 papers), Migraine and Headache Studies (5 papers), Muscle Physiology and Disorders (5 papers), Hepatitis C virus research (4 papers), Vascular Anomalies and Treatments (4 papers) and Cardiovascular Issues in Pregnancy (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (884 citations), Cardiology and Cardiovascular Medicine (508 citations), Physiology (80 citations), Sensory Systems (81 citations) and Physiology (428 citations). Gary Layton has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Robyn J. Barst, Anthony Ford, Kimberley Holt, Rayid Abdulqawi, Bruce G. McCarthy, Rachel Dockry, John A. Smith, Tomás Pulido, D. Dunbar Ivy and Marjana Serdarevic-Pehar. Their work appears in journals such as British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology, Antimicrobial Agents and Chemotherapy, Circulation and Neuromuscular Disorders.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact